Interrogating Syngeneic Models in Large Scale, How to Use Immunoprofiling Data to Improve your Studies
Presenter: Dr. Henry Q Li, Crown Bioscience
Syngeneic models are a standard preclinical platform for evaluating immunotherapies. However, using single, standalone models is less meaningful or productive when testing pharmaceuticals, particularly immunotherapeutics, with diverse mechanisms of action.
To overcome this issue, syngeneic models can be used in a large scale screening platform to assess novel immuno-oncology agents, aiming to rapidly identify model-specific efficacy, resistance, pharmacodynamic effects, and unique combination strategies.
Using a panel of 12 commonly used syngeneic models in this large scale modality, a comprehensive immunoprofiling study has recently been completed to fast-track the in vivo screening of the effects of PD-1, PD-L1, and CTLA-4 blockade. The efficacy and immunophenotyping readouts from this study are helping to address a number of current scientific and technical questions such as:
- Which models respond to ICI blockade and what is the degree of response?
- What are the baseline tumor infiltrating immune characteristics of each model at different time points?
- Which PD parameter is associated with efficacy in different models?
- Which baseline parameters are most predictive of efficacy?
- Does time point/tumor size affect reliability of tumor infiltrate analysis?
Watch This Webinar To Discover:
- How utilizing a large-scale, staggered syngeneic platform can improve efficiency and reproducibility while reducing drug development costs
- How comprehensive efficacy benchmarking (PD-1/PD-L1/CTLA-4), immunophenotyping, and profiling data can be utilized to address key questions in study design
- How RNAseq data and FACS/IHC analysis can be used for biomarker discovery to predict response
About The Presenter:
Henry QX Li, PhD leads CrownBio's Global Scientific Research and Innovation Division, focused on accelerating the creation of new, innovative products and services for discovery and translational sciences. Prior to this, Dr. Li successfully led and expanded CrownBio’s patient-derived xenograft (PDX) based Translational Oncology platform (2011-2016), and led the Biomarker and Diagnostic Technologies Division developing novel proprietary translational technologies for precise cancer diagnosis, predictive biomarker discovery, immuno-oncology biomarker detection and quantification, as well as rare cell identification and characterization (2016-2018).
Before joining CrownBio, Dr. Li gained over 20 years of biopharmaceutical, as well as academic R&D, experience in cancer and viral infection, including leadership roles as R&D Director/Senior Director in several US-based biotech companies. Dr. Li currently holds visiting Professor position at Peking University-State Key Laboratory.
Dr. Li earned his PhD in Molecular Biology/Biochemistry from the University of California (Irvine) and completed his postdoctoral training at UCLA School of Medicine. He has published more than 60 manuscripts and edited 3 books in the biopharmaceutical areas. He is also on the editorial board of Current Signal Transduction Therapy.